Astellas Pharma Inc.
Settlement with Lupin and Zydus in Myrbetriq® Patent Infringement Lawsuit
Astellas Pharma reached a settlement with Lupin and Zydus in the Myrbetriq® patent infringement lawsuit, receiving a total of USD 60 million in settlement payments and USD 150 million in upfront license fees.
Key Figures
- Settlement payment received: USD 60 million
- Upfront license fee: USD 150 million
- Impact on full-year consolidated results: Under review
AI要約
Overview of Settlement Agreement
Astellas Pharma entered into a settlement agreement with Lupin Limited and Zydus Lifesciences Limited regarding the United States patent infringement lawsuit related to Myrbetriq®, an overactive bladder treatment. Under the settlement, the two companies will pay a total of USD 60 million in settlement payments and USD 150 million in upfront license fees, as well as license fees per unit of the relevant products. This resolves all litigation concerning Myrbetriq®.
Future Outlook and Impact
The impact of this settlement on the full-year consolidated results for the fiscal year ending March 2026 is currently under review, and details have not been disclosed. While specific financial figures related to future earnings are unknown, receipt of settlement payments and license fees is expected to have a positive financial effect.
